Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash & Equivalents (2022 - 2025)

Maravai Lifesciences Holdings has reported Cash & Equivalents over the past 4 years, most recently at $216.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $216.9 million for Q4 2025, down 32.73% from a year ago — trailing twelve months through Dec 2025 was $216.9 million (down 32.73% YoY), and the annual figure for FY2025 was $216.9 million, down 32.73%.
  • Cash & Equivalents for Q4 2025 was $216.9 million at Maravai Lifesciences Holdings, down from $243.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for MRVI hit a ceiling of $632.1 million in Q4 2022 and a floor of $216.9 million in Q4 2025.
  • Median Cash & Equivalents over the past 4 years was $567.4 million (2024), compared with a mean of $451.5 million.
  • Biggest five-year swings in Cash & Equivalents: dropped 0.25% in 2024 and later tumbled 57.87% in 2025.
  • Maravai Lifesciences Holdings' Cash & Equivalents stood at $632.1 million in 2022, then dropped by 9.04% to $575.0 million in 2023, then plummeted by 43.93% to $322.4 million in 2024, then tumbled by 32.73% to $216.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $216.9 million (Q4 2025), $243.6 million (Q3 2025), and $269.9 million (Q2 2025) per Business Quant data.